FEELM
1.7.2022 10:09:09 CEST | Business Wire | Press release
Industry and Information Technology Bureau of Shenzhen Municipality announced the list of the second batch of industrial design development support program in 2022. SMOORE, along with Shenzhen Skyworth, DJI and other technology companies were shortlisted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005128/en/
The industrial design development support program supports the recognized industrial design centers or industrial design team of enterprises with strong innovation capabilities, design distinctiveness, and key competencies.
Meanwhile, the Industry and Information Technology Bureau of Shenzhen Municipality requests the shortlisted parties to lead and support both the advanced manufacturing and prevailing traditional industries with industrial design capability. Ultimately, enterprises shall achieve improvements in four aspects: external appearance, friendly user experience, branding and quality assurance, further to convert the improvements to deployment.
The public information of the shortlist announcement discloses that in-house industrial design team of FEELM, the flagship atomization tech brand of SMOORE wins the recognition out of its "innovative design and achievement transformation of closed-pod electronic atomizer based on leadless ceramic heating technology."
FEELM industrial design team has created a number of design works that combine technological attributes, practicality and consumer caring, empowering FEELM’s electronic atomization solution to connect consumer experience with advanced smart manufacturing.
From 2020 to 2022, FEELM industrial design team has won 8 prestige International design awards including the Red Dot Award, the iF Design Award, the German National Design Award and the MUSE Design Award.
In 2022, 4 product designs of FEELM won Red Dot Product Design Award, known as the "Oscar" of global industrial design at once. Among it, the vape design inspired from the design ingenuity of lipstick, which the nozzle can be twisted to hide the mouthpiece from getting on dusts receives positive feedbacks due to the clean and hygiene product experience it brings.
Another awarded product design is FEELM eco-friendly disposable e-cigarette. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence to reduce the excessive consumption of packaging materials.
Meanwhile, one of the key competencies of FEELM – the automation capacity can ensure mass production of innovative, design-led products, to be further launched in global consumer market through FEELM’s global business partners.
As a global leading vaping tech brand, the industrial design concepts presented by FEELM is not only own manifestation of social responsibility, but also a shorthand to show brand innovation capabilities, R&D investment, talent construction, and business performance.
The head of FEELM Industrial design team, Totom Lu says, "FEELM design devotes to helping clients in improving user experience from the perspective of vaping tech brand, keep pushing it to the new heights. I think the future direction of design of closed-pod vaping solution should lean on 3 dimensions: product experience; emotional experience, which is to identify problems before users notice them and sustainable experience, to focus on product sustainability."
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share, in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005128/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom